Healthcare provider profile · identity verified

Sula M Safar, DO

Family Practice · CHINO HILLS, CA · NPI 1225294713

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	234	76
Amlodipine Besylate	Amlodipine Besylate	197	59
Losartan Potassium	Losartan Potassium	192	60
Levothyroxine Sodium	Levothyroxine Sodium	147	39
Rosuvastatin Calcium	Rosuvastatin Calcium	109	35
Lisinopril	Lisinopril	105	32
Metformin Hcl	Metformin Hcl	105	33
Omeprazole	Omeprazole	90	31
Metoprolol Succinate	Metoprolol Succinate	77	19
Albuterol Sulfate Hfa	Albuterol Sulfate	74	21
Gabapentin	Gabapentin	70	21
Carvedilol	Carvedilol	57	14
Atenolol	Atenolol	54	17
Alendronate Sodium	Alendronate Sodium	52	15
Benazepril Hcl	Benazepril Hcl	49	11
Sertraline Hcl	Sertraline Hcl	49	12
Metoprolol Tartrate	Metoprolol Tartrate	46	14
Escitalopram Oxalate	Escitalopram Oxalate	45	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	42	12
Diclofenac Sodium	Diclofenac Sodium	40	14
Januvia	Sitagliptin Phosphate	40	13
Hydrochlorothiazide	Hydrochlorothiazide	38	14
Memantine Hcl	Memantine Hcl	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	suppressed
Famotidine	Famotidine	33	12
Pravastatin Sodium	Pravastatin Sodium	31	11
Lactulose	Lactulose	30	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	30	suppressed
Ibuprofen	Ibuprofen	29	11
Meloxicam	Meloxicam	29	12
Trazodone Hcl	Trazodone Hcl	29	suppressed
Furosemide	Furosemide	27	11
Hydroxyzine Hcl	Hydroxyzine Hcl	27	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	27	suppressed
Eliquis	Apixaban	26	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Montelukast Sodium	Montelukast Sodium	25	11
Wixela Inhub	Fluticasone Propion/Salmeterol	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Baclofen	Baclofen	23	16
Synthroid	Levothyroxine Sodium	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Fluticasone Propionate	Fluticasone Propionate	22	14
Glipizide	Glipizide	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Alprazolam	Alprazolam	20	suppressed
Finasteride	Finasteride	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	11
Nystatin	Nystatin	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Mounjaro	Tirzepatide	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	16
Trulicity	Dulaglutide	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Jardiance	Empagliflozin	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Potassium Chloride	Potassium Chloride	15	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Indomethacin	Indomethacin	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Ozempic	Semaglutide	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error